

# **CELL-PENETRATING ANTIBODIES FOR TARGETING HIV-1 P24 CAPSID PROTEIN**

**TEOW SIN YEANG**

**UNIVERSITI SAINS MALAYSIA**

**2015**

**CELL-PENETRATING ANTIBODIES FOR  
TARGETING HIV-1 P24 CAPSID PROTEIN**

by

**TEOW SIN YEANG**

**Thesis submitted in fulfillment of the requirements**

**for the degree of**

**Doctor of Philosophy**

**AUGUST 2015**

## ACKNOWLEDGEMENTS

I would like to thank my supervisor Dr. Syed Atif Ali for his continued support, guidance and valuable advice throughout my PhD studies. I would also like to extend my gratitude for my co-supervisors Prof. Dr. Narazah Mohd. Yusoff and Prof. Tan Soo Choon for their help and guidance.

I would like to acknowledge AMDI student fund (USM/IPPT/2000/G-2/xiv) and USM Postgraduate Research Grant Scheme (PRGS) (1001/CIPPT/846048) for funding this work. This research was also partly supported by Fundamental Research Grant Scheme (FRGS), from Ministry of High Education (203/CIPPT/6711206, MOHE). I would also like to thank MyBrain15, MOHE (KPT(B)890416075223) for offering the scholarship to financially support my PhD.

I am especially grateful to the facilities provided by the lab of Oncological and Radiological Sciences Cluster and MALDI-TOF MS provided by INFORMM, USM through Prof. Tan Soo Choon. A special thanks to my colleague Siti Aisyah for her kind help in molecular cloning of pSA-p24 vector and mice immunization and Miss Ang Chee Wei from INFORMM to analyze the sample using MALDI-TOF. A million thanks to other lab mates: Alif, Tasyriq, Yik Wei, and Nurdianah for continued assistance and encouragement and to provide such an enjoyable working atmosphere.

Finally, I would also like to express my deep gratitude to my mum, brothers, sister and my wife for their encouragement and tolerance.

## TABLE OF CONTENTS

	Page
<b>ACKNOWLEDGEMENTS.....</b>	<b>ii</b>
<b>TABLE OF CONTENTS.....</b>	<b>iii</b>
<b>LIST OF TABLES .....</b>	<b>x</b>
<b>LIST OF FIGURES .....</b>	<b>xiii</b>
<b>LIST OF ABBREVIATIONS .....</b>	<b>xix</b>
<b>LIST OF PUBLICATIONS.....</b>	<b>xxiv</b>
<b>ABSTRAK .....</b>	<b>xxv</b>
<b>ABSTRACT.....</b>	<b>xxvii</b>
<b>1 INTRODUCTION .....</b>	<b>1</b>
<b>1.1. HIV/AIDS pathogenesis .....</b>	<b>1</b>
1.1.1. Acquired Immunodeficiency Syndrome (AIDS) .....	1
1.1.2. Human Immunodeficiency Virus (HIV) .....	5
1.1.3. Disease control of AIDS .....	10
1.1.4. Drawbacks of current therapies.....	16
<b>1.2. Capsid protein in HIV-1 infectivity .....</b>	<b>18</b>
1.2.1. Biological function of capsid protein.....	18
1.2.2. Structure of capsid protein .....	21
1.2.3. Capsid protein as therapeutic target .....	25
<b>1.3. Antibody therapy against HIV-1.....</b>	<b>29</b>
1.3.1. Therapeutic antibodies .....	29
1.3.2. Antibody engineering.....	33
1.3.3. Antibody-mediated therapy against HIV-1 .....	35
1.3.4. Limitations of antibody-mediated therapy against HIV-1 .....	40
<b>1.4. Cell penetrating peptides (CPPs) .....</b>	<b>42</b>
1.4.1. Basic properties and classes.....	42
1.4.2. Cargo delivery by CPPs .....	46
1.4.3. CPP conjugation with cargo protein .....	49
1.4.4. Mechanism of CPP-mediated membrane translocation .....	50
1.4.5. CPPs for antiviral therapies.....	56

1.4.6. Construction of TransMAbs.....	58
<b>1.5. Research aim .....</b>	<b>60</b>
1.5.1. Overview of research .....	60
1.5.2. Research objectives .....	63
<b>2. CHARACTERIZATION OF P24 PROTEIN AND ANTI-P24 ANTIBODY .....</b>	<b>64</b>
<b>2.1. Targeting HIV-1 capsid protein .....</b>	<b>64</b>
<b>2.2. Materials and Methods .....</b>	<b>66</b>
2.2.1. Bacterial strains, plasmids, and media .....	66
2.2.2. Construction of vector expressing recombinant <i>p24</i> protein .....	66
2.2.3. Heat-shock transformation .....	72
2.2.4. Colony PCR of transformed bacteria .....	72
2.2.5. Restriction analysis and DNA sequencing of plasmid .....	75
2.2.6. Expression of <i>p24</i> protein .....	75
2.2.7. Cell lysis and protein extraction .....	76
2.2.8. Manual purification of <i>p24</i> protein .....	77
2.2.9. Automated purification of protein using AKTA purifier system .....	78
2.2.10. HIV-1 <i>p24</i> murine hybridoma cell culture .....	79
2.2.11. Purification of anti- <i>p24</i> MAbs using AKTA purifier system .....	80
2.2.12. Protein dialysis and concentration .....	80
2.2.13. Polymerization of recombinant <i>p24</i> proteins .....	81
2.2.14. Total protein assay and SDS-PAGE analysis .....	82
2.2.15. Western blot analysis .....	83
2.2.16. In-house <i>p24</i> indirect ELISA .....	84
2.2.17. Statistical analysis .....	84
<b>2.3. Construction of recombinant capsid expression plasmid .....</b>	<b>85</b>
2.3.1. Cloning of <i>p24</i> gene into pSA vector .....	85
2.3.2. Production of pSA- <i>p24</i> -6His .....	88
<b>2.4. Expression and purification of <i>p24</i> protein .....</b>	<b>91</b>
2.4.1. Optimization of IPTG induction .....	92
2.4.2. Effect of rare transfer RNA (tRNA) supplementation .....	98
2.4.3. Effect of cultivation medium .....	102

2.4.4. Purification of HIV-1 <i>p24</i> protein.....	104
2.4.5. Characterization of HIV-1 capsid protein.....	115
<b>2.5. Purification of anti-<i>p24</i> monoclonal antibodies .....</b>	<b>118</b>
2.5.1. Characterization of anti- <i>p24</i> MAbs.....	119
2.5.2. Binding activity of purified anti- <i>p24</i> MAbs .....	128
2.5.3. Polymerization inhibition of anti- <i>p24</i> MAbs.....	133
<b>2.6. Conclusions.....</b>	<b>136</b>
<b>3. CHARACTERIZATION OF CPP-ANTIBODY CONJUGATES .....</b>	<b>138</b>
<b>3.1. Construction of CPP-antibody .....</b>	<b>138</b>
<b>3.2. Materials and Methods .....</b>	<b>140</b>
3.2.1. CPPs and antibodies.....	140
3.2.2. Mammalian cell culture .....	140
3.2.3. Chemical conjugation of antibodies and CPPs .....	141
3.2.4. Antibody treatment of cell and preparation of cell lysates .....	144
3.2.5. Monocytic Fc Receptor (FcR) Blocking.....	146
3.2.6. Characterization of cellular uptake .....	146
3.2.7. Cytotoxicity assay .....	147
3.2.8. Assessment of antibody internalization by in-house <i>p24</i> ELISA .....	148
3.2.9. Antibody labeling by NHS-Fluorescein kit .....	148
3.2.10. Assessment of antibody internalization by fluorescence microscopy .....	150
3.2.11. Statistical analysis .....	151
<b>3.3. Chemical conjugation of antibody with CPP .....</b>	<b>152</b>
3.3.1. Construction of antibody-CPP conjugates .....	152
<b>3.4. Cellular delivery of antibody-CPP conjugates.....</b>	<b>160</b>
3.4.1. Antibody internalization in epithelial cell.....	161
3.4.2. Antibody internalization in T-lymphocytes .....	167
3.4.3. Antibody internalization in monocytes .....	172
<b>3.5. Cytotoxicity of antibody-CPP conjugates.....</b>	<b>182</b>
<b>3.6. Factors affecting internalization of conjugates.....</b>	<b>184</b>
3.6.1. Concentration of CPP-antibody conjugates .....	185
3.6.2. Molar ratios of CPPs versus antibody.....	189

3.6.3. Temperature .....	191
3.6.4. Availability of energy .....	197
<b>3.7. Mechanism of cellular uptake .....</b>	<b>202</b>
3.7.1. Clathrin-mediated endocytosis.....	204
3.7.2. Caveolae-mediated endocytosis.....	211
3.7.3. Cell surface binding of sialic acid.....	217
<b>3.8. Conclusions.....</b>	<b>221</b>
<b>4. ANTI-HIV ACTIVITY OF ANTIBODY-CPP CONJUGATES.....</b>	<b>224</b>
<b>4.1. TransMAbs as anti-HIV therapeutics .....</b>	<b>224</b>
<b>4.2. Materials and Methods .....</b>	<b>226</b>
4.2.1. Plasmids .....	226
4.2.2. Mammalian cell culture .....	228
4.2.3. Culture of PBMCs and primary CD4 <sup>+</sup> -T-cells isolation.....	229
4.2.4. Calcium phosphate transfection .....	230
4.2.5. Optimization of cell transfection using commercial reagents.....	231
4.2.6. Preparation of HIV-1 stocks .....	232
4.2.7. Optimization of multiplicity of infection (MOI) in various cells .....	233
4.2.8. Conjugation of anti-p24 MAbs with horseradish peroxidase (HRP).....	234
4.2.9. In-house HIV-1 p24 sandwich ELISA.....	235
4.2.10. HIV-1 infectivity assay by MAGI-CCR5 cells.....	236
4.2.11. Inhibition studies of HIV-1 by conjugated antibodies .....	237
4.2.12. Statistical analysis .....	239
<b>4.3. Plasmids.....</b>	<b>240</b>
<b>4.4. Optimization of transfection protocols .....</b>	<b>244</b>
<b>4.5. Stability of antibody-CPP conjugates .....</b>	<b>249</b>
4.5.1. Storage conditions of antibody-CPP conjugates.....	250
4.5.2. Stability of conjugates in extracellular condition .....	251
4.5.3. Stability of conjugates in intracellular condition .....	253
4.5.4. Ratios of extracellular and intracellular conjugates.....	255
<b>4.6. Optimization of assay for HIV titration .....</b>	<b>257</b>
4.6.1. Sandwich p24 ELISA.....	257

4.6.2. MAGI-CCR5 assay for HIV-1 infectivity .....	262
<b>4.7. Antiviral activities of conjugates .....</b>	<b>269</b>
4.7.1. Inhibition of single-cycle HIV-1 infection.....	270
4.7.2. Inhibition of HIV-1 infection in CD4 <sup>+</sup> -T-lymphocytic cell lines .....	281
4.7.3. Inhibition of HIV-1 infection in monocytic cell lines.....	295
4.7.4. Inhibition of HIV-1 infection in PBMCs .....	310
4.7.5. Inhibition of HIV-1 infection in primary CD4 <sup>+</sup> -T-cells.....	322
<b>4.8. Conclusions.....</b>	<b>329</b>
<b>5. DISCUSSION AND CONCLUSION .....</b>	<b>330</b>
<b>5.1. General discussion .....</b>	<b>330</b>
<b>5.2. Conclusion .....</b>	<b>336</b>
<b>5.3. Future work.....</b>	<b>337</b>
<b>6. REFERENCES .....</b>	<b>338</b>
<b>7. APPENDICES.....</b>	<b>374</b>
<b>Appendix A: Culture Media .....</b>	<b>374</b>
A1. Luria Bertani (LB) broth .....	374
A2. LB broth with 60% glycerol.....	374
A3. M9 minimal broth .....	374
A4. Super broth (SB) .....	375
A5. Terrific broth (TB) .....	375
A6. SOB medium.....	375
A7. SOC medium.....	376
A8. Addition of antibiotics/ supplements to the media.....	376
A9. Complete RPMI1640 .....	376
A10. Complete Dulbecco's Modified Eagle's Medium (DMEM) .....	377
A11. Complete DMEM with antibiotics.....	377
<b>Appendix B: General buffers, stock solutions, antibiotics.....</b>	<b>378</b>
B1. Antibiotic Ampicillin stock.....	378
B2. Antibiotic Chloramphenicol stock .....	378
B3. Antibiotic Gentamicin stock .....	378
B4. Antibiotic G418 stock .....	378



B5.	Antibiotic Hygromycin stock.....	379
B6.	Antibiotic Kanamycin stock.....	379
B7.	Antibiotic Penicillin stock.....	379
B8.	Antibiotic Puromycin stock .....	379
B9.	Antibiotic Streptomycin stock .....	380
B10.	BES-buffered saline (BBS).....	380
B11.	Calcium chloride 5M .....	380
B12.	Calcium chloride 2.5M .....	380
B13.	Carbonate coating buffer (p24 indirect ELISA) .....	381
B14.	Carbonate coating buffer (p24 sandwich ELISA).....	381
B15.	Coomassie Brilliant blue.....	381
B16.	DEAE-dextran.....	381
B17.	Disruption buffer (p24 sandwich ELISA).....	381
B18.	Ethanol 20% .....	382
B19.	Ethanol 70% .....	382
B20.	Ethidium bromide .....	382
B21.	Glucose.....	382
B22.	Glycine.....	382
B23.	HEPES .....	383
B24.	HEPES-buffered saline (HBS).....	383
B25.	Hydrochloric acid (HCl) .....	383
B26.	L-glutamine .....	383
B27.	Magnesium chloride.....	383
B28.	MES buffer.....	384
B29.	Methy-beta-cyclodextrin (M $\beta$ CD) .....	384
B30.	Nocodazole.....	384
B31.	PMSF.....	384
B32.	Phenol red .....	384
B33.	Phosphate buffered saline (PBS) stock .....	385
B34.	PBS solution.....	385
B35.	PBS with 0.05% Tween 20 (PBS-T).....	385

B36.	PBS with 5% skimmed milk (M-PBS) .....	385
B37.	Poly-lysine .....	385
B38.	Potassium ferricyanide .....	385
B39.	Potassium ferrocyanide .....	386
B40.	SDS-PAGE gel.....	386
B41.	SDS-PAGE Orange G loading buffer .....	387
B42.	Sialic acid stock .....	387
B43.	Sodium azide.....	387
B44.	Sodium acetate .....	388
B45.	Sodium bicarbonate.....	388
B46.	Sodium phosphate buffer .....	388
B47.	Sodium phosphate buffer with 5M NaCl .....	388
B48.	Sodium phosphate buffer with 500mM NaCl and 10mM imidazole.....	389
B49.	Sodium phosphate buffer with 500mM NaCl and 150mM imidazole.....	389
B50.	Sodium phosphate buffer with 300mM NaCl .....	389
B51.	Sodium phosphate buffer with 300mM NaCl and 5mM imidazole.....	389
B52.	Sodium phosphate buffer with 300mM NaCl and 150mM imidazole.....	389
B53.	Sodium pyruvate .....	390
B54.	Sulfuric acid .....	390
B55.	TBS stock.....	390
B56.	TBS solution .....	390
B57.	TBS-T.....	390
B58.	Towbin stock.....	390
B59.	Towbin buffer .....	391
B60.	Tris.....	391
B61.	Tris-HCl .....	391
B62.	Tris-SDS-Gly stock.....	391
B63.	Tris-SDS-Gly buffer .....	391
B64.	Triton X-100 lysis buffer .....	391
B65.	X-gal.....	392

## LIST OF TABLES

<b>Table</b>	<b>Page</b>
1.1. Summary of functions of genes encoded in HIV-1 genome.....	9
1.2. List of FDA-approved anti-HIV drugs.....	11
1.3. Side effects of HAART.....	17
1.4. Antiviral agents targeting HIV-1 CA protein.....	26
1.5. Monoclonal antibodies approved by US FDA and EU EMEA for clinical use.....	32
1.6. Monoclonal antibodies and antibody-based proteins as HIV-1 inhibitors..	37
1.7. HIV-1-neutralizing antibodies that target internal viral proteins.....	39
1.8. Physicochemical properties of common CPPs.....	43
1.9. Classification of CPPs based on origins.....	45
1.10. Cellular deliveries of macromolecules by CPPs in mammalian cells.....	48
1.11. Endocytosis inhibitors used in studying CPP-mediated cellular uptake.....	55
2.1. Details of oligonucleotide primers used for synthesis of pSA-vector and <i>p24</i> insert.....	68
2.2. Components and conditions of PCR for synthesis of <i>p24</i> insert.....	69
2.3. Components and conditions of inverse PCR for synthesis of pSA vector...	70
2.4. Components of PCR used in RE digestion and ligation of pSA-vector and <i>p24</i> insert.....	71
2.5. Details of oligonucleotide primers used for colony PCR of pSA- <i>p24</i> -6His.....	73
2.6. Components and conditions for colony PCR.....	74
2.7. Rare codon analysis of ORF coding for HIV-1 <i>p24</i> gene.....	99
2.8. Yield and percentage recovery of recombinant HIV-1 <i>p24</i> protein after each purification steps.....	112

<b>2.9.</b>	Percent recovery of purified HIV-1 <i>p24</i> after dialysis and concentration....	113
<b>2.10.</b>	Banding patterns of different immunoglobulin isotypes and antibody format under SDS-PAGE.....	125
<b>2.11.</b>	Percent recovery of purified anti- <i>p24</i> MAbs ATCC after dialysis and concentration.....	127
<b>3.1.</b>	Concentration of CPPs required for chemical cross-linking of MAbs.....	143
<b>3.2.</b>	Final concentration of antibodies used in internalization assay.....	145
<b>3.3.</b>	CPPs used for antibody conjugation.....	154
<b>3.4.</b>	Percent recovery of anti- <i>p24</i> MAbs for CPP-conjugation after dialysis.....	155
<b>3.5.</b>	Cytotoxicity of CPP-conjugated antibodies in cells.....	183
<b>3.6.</b>	Cytotoxicity of anti- <i>p24</i> MAbs in various cells.....	188
<b>4.1.</b>	Components used in restriction analysis of plasmid DNA.....	227
<b>4.2.</b>	Transfection efficiency of three transfection reagents at different DNA: reagent ratios.....	248
<b>4.3.</b>	Percentage of HIV-1 inhibition in 293T cells at single exposure of conjugates.....	275
<b>4.4.</b>	Percentage of HIV-1 inhibition in 293T cells at multiple exposure of conjugates.....	279
<b>4.5.</b>	Percentage of HIV-1 inhibition in Jurkat-T cells at single exposure of conjugates.....	286
<b>4.6.</b>	Percentage of HIV-1 inhibition in Jurkat-T cells at multiple exposure of conjugates.....	289
<b>4.7.</b>	Percentage of HIV-1 inhibition in H9 cells at single exposure of conjugates .....	292
<b>4.8.</b>	Percentage of HIV-1 inhibition in H9 cells at multiple exposure of conjugates.....	294
<b>4.9.</b>	Percentage of HIV-1 inhibition in THP-1 cells at single exposure of conjugates.....	298

<b>4.10.</b>	Percentage of HIV-1 inhibition in THP-1 cells at multiple exposure of conjugates.....	300
<b>4.11.</b>	Percentage of HIV-1 inhibition in U937 cells at single exposure of conjugates.....	303
<b>4.12.</b>	Percentage of HIV-1 inhibition in U937 monocytic cells at multiple exposure of conjugates.....	305
<b>4.13.</b>	Percentage of HIV-1 inhibition in PBMCs at single exposure of conjugates.....	314
<b>4.14.</b>	Percentage of HIV-1 inhibition in PBMCs at multiple exposures of conjugates .....	318
<b>4.15.</b>	Percentage of HIV-1 inhibition in PBMCs by various anti- <i>p24</i> -TransMAbs.....	321
<b>4.16.</b>	Percentage of HIV-1 inhibition in primary CD4 <sup>+</sup> -T-cells at single exposure of conjugates.....	324
<b>4.17.</b>	Percentage of HIV-1 inhibition in primary CD4 <sup>+</sup> -T-cells at multiple exposures of conjugates.....	326

## LIST OF FIGURES

<b>Figure</b>	<b>Page</b>
1.1. Levels of CD4 <sup>+</sup> -T-lymphocytes and HIV RNA copies throughout AIDS Progression.....	3
1.2. Occurrence of opportunistic infections and cancers over the course of HIV infection.....	4
1.3. Structure of immature and mature forms of HIV-1.....	6
1.4. The HIV-1 genome, transcripts, and proteins.....	7
1.5. HIV-1 replication cycle and potential antiviral targets.....	13
1.6. Increased survival rates of AIDS by HAART.....	15
1.7. Assembly of Gag on cell membrane and its proteolytic cleavage.....	20
1.8. Characterization of HIV-1 CA hexameric lattice.....	22
1.9. Cryo-EM reconstruction of HIV-1 CA tubular assembly.....	23
1.10. Chemical structures of inhibitors targeting HIV-1 CA.....	28
1.11. Structure of antibody isotypes.....	30
1.12. Principle steps in hybridoma technology.....	34
1.13. HIV-1 neutralizing monoclonal antibodies (MAbs) and their targets.....	38
1.14. Models of CPPs cellular uptake.....	53
1.15. Cell entry of cargoes by endocytic pathways.....	54
1.16. Project workflow.....	62
2.1. Diagram representing the construction of pSA- <i>p24</i> -6His and <i>p24</i> protein expression.....	86
2.2. Graphical representation of recombinant strategy for pSA- <i>p24</i> -6His.....	87
2.3. Cloning verification of pSA- <i>p24</i> -6His.....	90

<b>2.4.</b>	SDS-PAGE/ Western blot analysis of induced and un-induced bacterial culture.....	94
<b>2.5.</b>	Optimization of IPTG concentration for <i>p24</i> expression.....	96
<b>2.6.</b>	Optimization of IPTG induction temperature and time for <i>p24</i> expression.	97
<b>2.7.</b>	Effect of rare tRNA supplementation on <i>p24</i> expression in NiCo21(DE3) <i>E. coli</i> .....	101
<b>2.8.</b>	Effect of cultivation medium composition on HIV-1 <i>p24</i> production.....	103
<b>2.9.</b>	Purification of HIV-1 <i>p24</i> expressed in NiCo21(DE3) <i>E. coli</i> .....	107
<b>2.10.</b>	Representative chromatogram of <i>p24</i> protein purification by FPLC.....	109
<b>2.11.</b>	SDS-PAGE analysis of protein fractions from <i>p24</i> purification by FPLC.....	110
<b>2.12.</b>	Protein-concentration-dependent polymerization of purified <i>p24</i> .....	116
<b>2.13.</b>	Salt-concentration-dependent polymerization of purified <i>p24</i> .....	117
<b>2.14.</b>	FPLC chromatogram profile of anti- <i>p24</i> MAbs (AIDS Reagent).....	121
<b>2.15.</b>	FPLC chromatogram profile of anti- <i>p24</i> MAbs (ATCC).....	122
<b>2.16.</b>	SDS-PAGE analysis in reducing condition of anti- <i>p24</i> MAbs (AIDS Reagent) purification by FPLC.....	123
<b>2.17.</b>	SDS-PAGE analysis in reducing condition of anti- <i>p24</i> MAbs (ATCC) purification by FPLC.....	124
<b>2.18.</b>	Reactivity of purified HIV-1 <i>p24</i> protein by ELISA.....	129
<b>2.19.</b>	Reactivity of anti- <i>p24</i> MAbs by ELISA.....	130
<b>2.20.</b>	Western Blot analysis of <i>p24</i> protein and anti- <i>p24</i> MAbs.....	132
<b>2.21.</b>	Polymerization inhibition of anti- <i>p24</i> MAbs ATCC.....	135
<b>3.1.</b>	SDS-PAGE analysis of non-conjugated and CPP-conjugated anti- <i>p24</i> MAbs in reducing condition.....	156
<b>3.2.</b>	MALDI-TOF analysis of MTS-conjugated and non-conjugated MAbs.....	159
<b>3.3.</b>	Penetration of CPP-conjugated MAbs into 293T cells.....	162

<b>3.4.</b>	Effect of trypan blue on extracellular fluorescence quenching.....	165
<b>3.5.</b>	Internalization of MTS-anti- <i>p24</i> antibodies at different time points in 293T cells.....	166
<b>3.6.</b>	Penetration of CPP-conjugated MAbs into Jurkat-T cells.....	168
<b>3.7.</b>	Penetration of CPP-conjugated MAbs into H9 cells.....	169
<b>3.8.</b>	Internalization of MTS-conjugated MAbs into Jurkat-T cells.....	171
<b>3.9.</b>	Penetration of CPP-conjugated MAbs into THP-1 cells.....	174
<b>3.10.</b>	Penetration of CPP-conjugated MAbs into U937 cells.....	176
<b>3.11.</b>	Internalization of MTS-conjugated MAbs into U937 cells.....	177
<b>3.12.</b>	Interaction of antibody Fc region to monocyte Fc receptor.....	179
<b>3.13.</b>	Effect of FcR blocking reagents on antibody transport in monocytes.....	180
<b>3.14.</b>	Concentration-dependence of MTS-conjugated anti- <i>p24</i> MAbs in cell penetration.....	186
<b>3.15.</b>	Cell penetration of conjugated antibodies at various molar ratios of CPPs versus antibodies.....	190
<b>3.16.</b>	Temperature dependency of antibody internalization in cells.....	193
<b>3.17.</b>	Percent inhibition of antibody internalization at 4°C .....	196
<b>3.18.</b>	Energy dependency of antibody internalization in cells.....	198
<b>3.19.</b>	Percent inhibition of antibody internalization following energy depletion.....	201
<b>3.20.</b>	Multiple steps involved in clathrin-dependent endocytosis.....	205
<b>3.21.</b>	Electron micrographs of early intermediates in clathrin-dependent endocytosis.....	206
<b>3.22.</b>	Clathrin-mediated endocytosis of antibody internalization in cells.....	208
<b>3.23.</b>	Percent inhibition of antibody internalization following Nocodazole treatment.....	210
<b>3.24.</b>	Multiple faces of caveolae.....	212



<b>3.25.</b>	Caveolae-mediated endocytosis of antibody internalization in cells.....	214
<b>3.26.</b>	Percent inhibition of antibody internalization following M $\beta$ CD treatment.....	216
<b>3.27.</b>	Sialic acid dependency of antibody internalization in cells.....	218
<b>3.28.</b>	Percent inhibition of antibody internalization following sialic acid treatment.....	220
<b>4.1.</b>	Restriction maps of pQBI-nefGFP and pNL4-3.....	241
<b>4.2.</b>	Restriction map of pWT-BaL.....	242
<b>4.3.</b>	Confirmation of plasmids by restriction analysis.....	243
<b>4.4.</b>	Representative images of transfection efficiency of three different transfection reagents at 24 hour post-transfection.....	245
<b>4.5.</b>	Representative images of transfection efficiency of three different transfection reagents at 48-hour post-transfection.....	246
<b>4.6.</b>	Stability of anti- <i>p24</i> antibodies in culture supernatant .....	252
<b>4.7.</b>	Retention of anti- <i>p24</i> MAbs reactivity inside the cells.....	254
<b>4.8.</b>	Level of internalization of anti- <i>p24</i> antibodies in 293T cells.....	256
<b>4.9.</b>	Common ELISA formats.....	258
<b>4.10.</b>	Effect of different concentrations of coated primary antibodies on sensitivity of sandwich <i>p24</i> ELISA.....	260
<b>4.11.</b>	Effect of different concentrations of secondary antibodies on sensitivity of sandwich <i>p24</i> ELISA.....	261
<b>4.12.</b>	Schematic diagram of MAGI assay for viral infectivity.....	263
<b>4.13.</b>	Images of HIV-1 infected MAGI-CCR5 blue cells.....	265
<b>4.14.</b>	Relationship of MAGI infectivity assay and <i>p24</i> ELISA.....	268
<b>4.15.</b>	Effect of X-tremeGene transfection reagent on antibody internalization....	272
<b>4.16.</b>	Single-exposure of anti- <i>p24</i> -TransMAbs in pNL4-3-transfected 293T cells.....	274

<b>4.17.</b>	Multiple-exposure of antibody conjugates in pNL4-3-transfected 293T cells.....	277
<b>4.18.</b>	Internalization of MTS-anti-AChE antibodies at different time point in 293T cells.....	280
<b>4.19.</b>	HIV-1 infection profiles of (A) Jurkat-T; and (B) H9 T-lymphocytic cell lines at different MOIs.....	283
<b>4.20.</b>	Single-exposure of antibody conjugates in HIV-1-infected Jurkat-T cells...	285
<b>4.21.</b>	Multiple-exposure of antibody conjugates in HIV-1-infected Jurkat-T cells.....	288
<b>4.22.</b>	Single-exposure of antibody conjugates in HIV-1-infected H9 cells.....	291
<b>4.23.</b>	Multiple-exposure of antibody conjugates in HIV-1-infected H9 cells.....	293
<b>4.24.</b>	HIV-1 infection profiles of (A) THP-1; and (B) U937 monocytic cell lines at different MOIs.....	296
<b>4.25.</b>	Single-exposure of antibody conjugates in HIV-1-infected THP-1 cells.....	297
<b>4.26.</b>	Multiple-exposure of antibody conjugates in HIV-1-infected THP-1 cells.	299
<b>4.27.</b>	Single-exposure of antibody conjugates in HIV-1-infected U937 cells.....	302
<b>4.28.</b>	Multiple-exposure of antibody conjugates in HIV-1-infected U937 cells...	304
<b>4.29.</b>	Effect of FcR blocking reagents on antiviral effects of anti- <i>p24</i> -TransMAbs against monocytes.....	307
<b>4.30.</b>	Morphology of ruthenium red (RR)-stained membranes in macrophages and virus localization in the HIV-1 assembly compartment.....	309
<b>4.31.</b>	HIV-1 infection profiles of (A) PBMCs; and (B) Primary CD4 <sup>+</sup> -T-lymphocytes at MOI 0.1 by HIV-1 NL4-3 and BaL.....	312
<b>4.32.</b>	Single-exposure of antibody conjugates in HIV-1 NL4-3 (A) and BaL (B) infected PBMCs.....	313
<b>4.33.</b>	Pre-treatment (A) and post-treatment (B) of antibody conjugates at multiple exposures in HIV-1 NL4-3-infected PBMCs.....	316
<b>4.34.</b>	Pre-treatment (A) and post-treatment (B) of antibody conjugates at multiple exposures in HIV-1 BaL-infected PBMCs.....	317

<b>4.35.</b>	Antiviral activities of anti- <i>p24</i> -TransMAbs against HIV-1-infected PBMCs .....	320
<b>4.36.</b>	Single-exposure of antibody conjugates in HIV-1 NL4-3 (A) and BaL (B) infected primary CD4 <sup>+</sup> -T-cells.....	323
<b>4.37.</b>	Multiple-exposure of antibody conjugates in HIV-1-NL4-3 (A) and BaL (B) infected primary CD4 <sup>+</sup> -T-cells.....	325
<b>4.38.</b>	Antiviral activities of TransMAbs in combination against HIV-1 NL4-3 (A) and BaL (B) infected primary CD4 <sup>+</sup> -T-cells.....	328

## LIST OF ABBREVIATIONS

AIDS	Acquired immunodeficiency syndrome
Amp	Ampicillin
Antp	Antennapedia
APS	Ammonium persulfate
ATP	Adenosine triphosphate
$\alpha$ -HGA	$\alpha$ -hydroxy-glycineamide
BES	N, N-bis (2-hydroxyethyl)-2-aminoethanesulfonic acid
bp	Base pair
BSA	Bovine serum albumin
CA	Capsid molecule or <i>p24</i>
CAP-1	N-(3-chloro-4-methylphenyl)-N'-{2-[(5-[(dimethylamino)-methyl]-2-furyl)-methyl)-sulfanyl]ethyl}urea
CAI	Capsid assembly inhibitor
CBD	Chitin-binding domain
CD	Cluster of differentiation
CDC	Centers for Disease Control and Prevention
CDRs	Complementarity-determining regions
CELISA	Cell-based enzyme-linked immunosorbent assay
CFU	Colony-forming unit
cm	Centimeter
CPP	Cell penetrating peptide
CV	Column volume
Da	Dalton
DC	Dendritic cells
DMEM	Dulbecco's modified eagle medium
DMSO	Dimethylsulfoxide

DNA	Deoxy ribonucleic acid
DSB	3-O-(3',3'-Dimethylsuccinyl) betulinic acid
EDTA	Ethylenediaminetetraacetic acid
ELISA	Enzyme-linked immunosorbent assay
EMEA	European Medicines Agency
Env	Envelope
EU	European Union
FBS	Fetal bovine serum
Fc	Constant fragment
FcR	Fc receptor
FDA	Food and Drug Administration
FPLC	Fast protein liquid chromatography
Gag	Group antigen
GAG	Glucoaminoglycans
G-NH <sub>2</sub>	Glycineamide
gp	Glycoprotein
GPG-NH <sub>2</sub>	Glycyl-prolyl-glycine-amide
HAART	Highly active antiretroviral therapy
HAMA	Human anti-mouse antibody
HEK293	Human embryonic kidney 293 cells
His	Histidine
HIV	Human immunodeficiency virus
hr	Hour
HRP	Horseradish peroxidase
HSPGs	Heparan sulfate proteoglycans
Ig	Immunoglobulin
IgG	Immunoglobulin gamma

IL-2	Interleukin-2
IMAC	Immobilized metal affinity chromatography
IPTG	Isopropylthio- $\beta$ -galactoside
kb	Kilo base
kDa	Kilo Dalton
KLH	Keyhole limpet hemocyanin
LB	Luria Bertani media
LTR	Long tandem repeats
MA	Matrix molecule or <i>p17</i>
MAb	Monoclonal antibody
MALDI-TOF	Matrix-assisted laser desorption/ionization time-of-flight
M $\beta$ CD	Methyl- $\beta$ -cyclodextrin
MDFF	Molecular dynamics flexible fitting
MBP	Maltose binding protein
MES	2-( <i>N</i> -morpholine)-ethanesulfonic acid
MHC	Major histocompatibility complex
mL	Mililiter
mm	Milimeter
mM	Milimolar
MTS	Membrane translocating sequence
MW	Molecular weight
NC	Nucleocapsid molecule or <i>p7</i>
Nc	Nitrocellulose
Nef	Negative factor
nm	Nanometer
OD	Optical density
ORF	Open reading frame

PCR	Polymerase chain reaction
PBMCs	Peripheral blood mononuclear cells
PBS	Phosphate buffered saline
pg	Picogram
pH	Potential hydrogen
PHA	Phytohemagglutinin
PNA	Peptide nucleic acid
Pol	Polymerase
PTD	Protein transduction domain
RBCs	Red blood cells
RBS	Ribosome binding site
RE	Restriction enzymes
Rev	Regulator of expression of viral proteins
RNA	Ribonucleic acid
RT	Room temperature
RT-PCR	Reverse transcriptase- polymerase chain reaction
scFv	Single chain variable fragments
sdAb	Single-domain antibody
SDS	Sodium dodecyl sulfate
SDS-PAGE	Sodium dodecyl sulfate polyarylamide gel electrophoresis
siRNA	Small interfering RNA
SP	Spacer peptide
TAE	Tris-Acetate-EDTA
Tat	Transactivator of transcription
TEMED	N,N,N\N'-tetramethylethylenediamine
TFA	Trifluoroacetic acid
US	United States

UV	Ultraviolet
Vif	Virus infectivity factor
Vpr	Viral protein r
Vpu	Viral protein u
WHO	World Health Organization
$\mu\text{m}$	Micrometer
$\mu\text{M}$	Micromolar
$\mu\text{L}$	Microliter
$^{\circ}\text{C}$	Degree Celsius



## LIST OF PUBLICATIONS

### Papers

**Teow, S.Y.** & Ali, S.A. A cell penetrating antibody targeting capsid protein (p24) inhibits the production of HIV-1 infectious particles. (Manuscript in preparation)

**Teow, S.Y.**, Mualif, S.A., Omar, T.C., Wei, C.Y., Yusoff, N.M., & Ali, S.A. (2013). Production and purification of polymerization-competent HIV-1 capsid protein p24 (CA) in NiCo21(DE3) *Escherichia coli*. *BMC Biotechnol.* **13(107)**.

### Conferences

**Teow, S.Y.**, Yusoff, N.M., Tan, S.C., & Ali, S.A. Chemical engineering of cell-penetrating antibodies for potent intracellular targetings. UTAR National Postgraduate Fundamental and Applied Sciences Seminar (NPFASS), UTAR Kampar, Perak, 14-15th June, 2014.

**Teow, S.Y.**, Yusoff, N.M., Tan, S.C., & Ali, S.A. Chemical engineering of cell-penetrating antibodies for targeting HIV-1 pathogenesis factor – p24 capsid protein. Monash Science Symposium, Monash University Malaysia, Bandar Sunway, Selangor, 18-19th June, 2014.

Mualif, S.A., **Teow, S.Y.**, Omar, T.C., Yusoff, N.M., & Ali, S.A. Construction of HIV-1 capsid protein p24 (CA) – specific single chain fv (scFv) phage display library: towards the development of novel therapeutic antibodies against HIV/AIDS. Monash Science Symposium, Monash University Malaysia, Bandar Sunway, Selangor, 18-19th June, 2014.

# ANTIBODI PENEMBUS SEL UNTUK MENSASARKAN PROTEIN KAPSID

## P24 HIV-1

### ABSTRAK

Protein kapsid *p24* memainkan peranan yang penting dalam peringkat awal dan akhir replikasi HIV. Justeru, kapsid HIV-1 dianggap sebagai sasaran penting dalam pembangunan ubat terapi baharu untuk merawat HIV/AIDS. Perencat peptida seperti *CAP-1*, *CAI* dan *NYAD-1* mampu menyekat fungsi kapsid HIV-1 dalam sel yang dijangkiti HIV. Walau bagaimanapun, sifat peptida yang kurang stabil dalam darah, menyebabkan ia cepat dilupuskan dari sistem malah kurang spesifik terhadap sasaran. Sebaliknya, antibodi monoklon (*MAB*) bersifat lebih stabil dan spesifik. Antibodi monoklon telahpun digunapakai sebagai modaliti terapi untuk merawat pelbagai penyakit termasuk kanser dan jangkitan virus. Namun, keberkesanan antibodi masih dipersoal kerana tidak dapat menembusi sel untuk menyasar sasaran dalam sel seperti kapsid HIV. Dengan ini, antibodi monoklon *anti-p24* telah dihasilkan secara kejuruteraan kimia dengan peptida penembus sel yang dapat mensasarkan sasaran *p24* dalam sel (*anti-p24-TransMAbs*). Dalam kajian ini, antibodi *anti-p24* telah dicantum dengan lapan jenis peptida penembus sel secara pengoksidaan *periodate*. Ujian *p24 ELISA* dan mikroskopi berpendafluor kemudiannya digunapakai untuk menilai tahap penembusan dalam sel. Antibodi *anti-p24* yang digabungkan dengan *MTS* mempunyai tahap penembusan sel yang paling berkesan. Penembusan sel ini adalah bergantung kepada kepekatan peptida dan hasil maksimum diperolehi selepas 24 jam rawatan. Rawatan setinggi 10µg/mL *anti-p24-TransMAbs* tidak menunjukkan sebarang kesan

toksik pada sel. Kajian mekanikal menunjukkan bahawa rawatan *anti-p24-TransMAbs* dalam monosit adalah bergantung kepada suhu and tenaga serta dikawal separa oleh endositosis *clathrin* dan *caveolae*. Sebaliknya, rawatan *anti-p24-TransMAbs* dalam limfosit T tidak bergantung kepada endositosis. Berdasarkan ujian sel *MAGI* untuk menyukat tahap jangkitan HIV-1, 10µg/mL *anti-p24-TransMAbs* berjaya mengurangkan tahap jangkitan HIV-1 sebanyak 66% dalam sel *Jurkat-T* dan 94% dalam sel *H9*, namun aktiviti lebih rendah dilihat dalam sel *THP-1* (38%) dan sel *U937* (27%). Tambahan pula, aktiviti virus dapat dikawal oleh antibodi ini dalam *PBMCs* (48%) dan sel *CD4<sup>+</sup>-T* (60%). Sebagai kesimpulan, *anti-p24-TransMAbs* berpotensi sebagai terapi HIV/AIDS yang baharu. Strategi yang sama juga boleh digunakan untuk menyasarkan protein HIV lain seperti *Nef*, *Vif* dan *Vpr*. Untuk meningkatkan aktiviti antibodi ini, kami memilih antibodi monoklon yang lebih reaktif dengan teknologi *phage-display*. Antibodi dalam format *scFv* ini sedang dihasilkan dan digabung dengan *MTS* secara molekular untuk menyasarkan kapsid dalam sel.

## **CELL-PENETRATING ANTIBODIES FOR TARGETING HIV-1 P24 CAPSID**

### **PROTEIN**

### **ABSTRACT**

The capsid protein plays seminal roles in both early and late stages of the HIV replication cycle. Hence, HIV-1 capsid protein is considered an important target for developing novel drugs to treat HIV/AIDS. Capsid molecule (CA)-targeting peptide inhibitors (CAP-1, CAI and NYAD-1) have been reported to disrupt the capsid protein functions in HIV-infected cells. However, the peptides are less stable in the blood, thus resulting in rapid clearance from the system and they can exhibit off-target activities. Monoclonal antibodies (MAbs) on the other hand, are stable and highly specific molecule, which have been successfully used as therapeutic modalities to treat various types of cancer and viral infections. Nonetheless, MAbs cannot penetrate into the cell and interact with intracellular target such as HIV-1 CA. To this end, anti-p24 MAbs were chemically engineered with cell-penetrating peptides (CPPs) to generate cell-penetrable (anti-p24-TransMAbs). In this study, anti-p24 MAbs were conjugated with 8 different CPPs through periodate oxidation. The cell penetration of anti-p24-TransMAbs was then examined by p24 ELISA and fluorescence microscopy. Anti-p24 MAbs conjugated with MTS (membrane-transduction sequence) resulted in most efficient penetration into the cells. The internalization of anti-p24-TransMAbs was concentration-dependent and maximum at 24 hours incubation. No toxicity was observed when the cells were treated with up to 10 $\mu$ g/mL anti-p24-TransMAbs. Mechanistic studies showed that the transportation of anti-p24-TransMAbs in promonocytic cell lines was

temperature- and energy-dependent, and partially mediated by clathrin and caveolae-dependent endocytic pathways. On the other hand, the transportation of anti-p24-TransMAbs in T-lymphocytic cell lines did not depend on endocytosis and resulted from CPP-mediated membrane perturbation. Using MAGI (multinuclear-activation galactosidase indicator) cell assay, the 10µg/mL anti-p24-TransMAbs successfully reduced the HIV-1 infectivity in Jurkat-T (66%) and H9 (94%) lymphocytic cell lines while lower inhibition was seen in infected THP-1 (38%) and U937 (27%) promonocytic cell lines. More promisingly, pronounced antiviral effects were seen in PHA-stimulated infected human PBMCs (48%), and infected primary human CD4<sup>+</sup>-T-cells (60%). We conclude that anti-p24-TransMAbs targeting HIV-1 CA can be developed into a novel HIV/AIDS therapy. Similar strategy can also be potentially applied on targeting other intracellular HIV-1 protein such as Nef, Vif and Vpr. To further enhance the antiviral activity of antibody, we are currently selecting the monoclonal antibody against the capsid protein by phage-display technology. The antibody in scFv format are being generated and molecularly conjugated with MTS to target and block the intracellular CA.

# **1 INTRODUCTION**


## **1.1. HIV/AIDS pathogenesis**

### **1.1.1. Acquired Immunodeficiency Syndrome (AIDS)**

AIDS is today's global life-threatening concern. Since its first identification in United States in 1981 (CDC Morbidity & Mortality Weekly Report, 1981), an increased number of infections and deaths attributed to AIDS have been reported. In 1983, Human Immunodeficiency Virus (HIV) was identified as the causative agent for AIDS (Barre-Sinoussi *et al.*, 1983). According to Joint United Nations Programme on HIV/AIDS (UNAIDS), approximately 35 million people worldwide were living with HIV/AIDS in 2013, and 19 million of them do not know that they have the virus. In 2013 alone, 1.5 million people have died of AIDS-related causes. Sub-Saharan Africa remains the region with highest number of reported cases in 2013 (24.7 million out of 35 million that accounts for 70.6% of global statistics) and more than 70% of all people of the country are living with HIV (UNAIDS Gap Report 2014). There are also a strikingly high number of AIDS-related cases in Malaysia. By the end of 2013, Malaysia had a cumulative number of 101,672 HIV-related cases, 20,235 reported AIDS and 16,340 AIDS-related deaths since the first occurrence in 1986 (Global AIDS Response Progress Report 2014).

In infected patients, the HIV presents either as free virus particles or lie within infected immune cells in biological fluids. HIV infects vital cells in the human immune system such as CD4<sup>+</sup>-T-lymphocytes, monocytes/macrophages, and dendritic cells (DCs). Notably, a HIV-positive individual may not necessarily be AIDS-positive due to the clinical latency period that can last up to ten years or longer. During this period, the


virus wears down the immune system, rendering the body susceptible to ‘opportunistic infections’ and other medical complications (**Figure 1.1**). The latter usually happens when the total CD4<sup>+</sup>-T-cells or "T-helper" cells, which are important component of the immune system, is less than 200 cells per cubic milliliter of blood (200 cells/mm<sup>3</sup>). Healthy individuals usually have 500 - 1,500 cells/mm<sup>3</sup>. The late stage of AIDS is often complicated by cancer and other opportunistic infections (**Figure 1.2**). These opportunistic infections are sufficient to cause death due to the non-functional immune system.



**Figure 1.1. Levels of CD4<sup>+</sup>-T-lymphocytes and HIV RNA copies throughout AIDS progression.** The graph shows the general relationship of CD4<sup>+</sup>-T-lymphocytes numbers (**blue line**) and viral load (**red line**) over the course of HIV infection. The CD4<sup>+</sup>-T-lymphocytes number drops during the first 6-week of primary infection while the HIV replicates and spreads to multiple organs. The HIV number then significantly drops after the successful infection and gradually increases during the clinical latency while the CD4<sup>+</sup>-T-lymphocytes drop every year. At the late stage of infection (CD4<sup>+</sup>-T-lymphocytes number is less than 200 cells/mm<sup>3</sup>), the immune system is compromised and attacked by multiple ‘opportunistic’ diseases. Due to the non-functional immune system, the HIV rapidly replicates to take over the body system.

Source: [youngdayschool.edu.uy/webliceo/aids.html](http://youngdayschool.edu.uy/webliceo/aids.html)






**Figure 1.2. Occurrence of opportunistic infections and cancers over the course of HIV infection.** During the primary infection, common symptoms of viral infections are seen such as fever and rashes. As the CD4<sup>+</sup>-T-cell count drops due to the HIV infection that compromises the immune system, the host becomes infected by more deadly infections (tuberculosis, pneumonia, candidiasis, *etc.*) and cancer diseases (lymphoma, sarcoma, *etc.*).

Adapted and modified from [southsudanmedicaljournal.com/archive/2009-08/untitled-resource.html](http://southsudanmedicaljournal.com/archive/2009-08/untitled-resource.html)

### 1.1.2. Human Immunodeficiency Virus (HIV)


HIV is an enveloped virus of 100-120nm containing two copies of approximately 9kb genomic RNA. HIV originates from *lentiviridae* subfamily of the *retroviridae* family, and there are two subtypes: HIV-1 and HIV-2. HIV-1 is more virulent and infective, thus contributing largely to the global infections whereas HIV-2 infection is only confined to West Africa (CDC Morbidity & Mortality Weekly Report, 2011). Upon viral entry into the target cells, the genomic RNA is reverse-transcribed into complementary DNA (9.8kb) and gets integrated into the host genome. The virus then becomes latent and can reside in the host cells for a long period of time. HIV-1 is morphologically spherical and it encodes a total of three structural proteins, two envelope proteins, three enzymes, and six accessory proteins (Turner and Summers, 1999).

The viral genomic material is surrounded by an outer coat or viral envelope (**Figure 1.3**), composing of two layers of host cell-derived phospholipids during the budding of viral particles. The envelope also consists of cap-like protruded proteins made up of three molecules of knob-like glycoprotein 120 (*gp120*), and a stem consisting of three spike-like molecules known as glycoprotein 41 (*gp41*) that anchor the structure in the viral envelope. Both of these envelope-associated protein are cleaved by protease from glycoprotein 160 (*gp160*) coded by *env* gene (**Figure 1.4**). These protein structures play important roles in establishing the HIV infection during the attachment and entry steps (Clapham and McKnight, 2002).



**Figure 1.3. Structure of immature and mature forms of HIV-1.** The mature HIV-1 contains a bullet-shaped core encapsulating RNA genome and viral enzymes whereas the immature HIV-1 has a 'hollow' centre due to the unprocessed *gag-pol* genes.

Source: [mcdb-webarchive.mcdb.ucsb.edu/sears/biochemistry/presentations/f07-student-presentations/Justine-Swann/frames6.htm](http://mcdb-webarchive.mcdb.ucsb.edu/sears/biochemistry/presentations/f07-student-presentations/Justine-Swann/frames6.htm)



**Figure 1.4. The HIV genome, transcripts, and proteins.** (a) HIV transcripts consist of 10kb viral genome containing open reading frames for 16 proteins that are synthesized from at least 10 transcripts. (b) *gag*, *pol* and *env* precursors are processed by the viral proteases to form HIV proteins essential and accessory for AIDS progression.

Source: Peterlin and Trono, 2003.

Within the viral envelope, a layer of matrix protein composing of viral protein, MA or *p17* helps to maintain the integrity of the virion particle. At the center of virus, there is a bullet-shaped core surrounded by a conical capsid made up of approximately 2,000 copies of the viral protein, CA or *p24* (Luciw, 1996). The viral core contains two single strands of RNAs that encode the HIV-1 genome. These RNAs are tightly bound to the nucleocapsid proteins that are composed of NC or *p7*. The core also contains a few other viral enzymes such as reverse transcriptase, ribonuclease, proteases, and integrase that play important roles in the replication cycle (Freed, 2001). Three of the structural proteins (MA, CA and NC) are encoded by *gag* gene whereas *pol* gene encodes for the viral enzymes.

Other than *env*, *gag* and *pol* genes, which are indispensable for HIV-1 replication, the RNA genome also contains other regulatory genes such as *nef*, *tat*, *rev*, *vpu*, *vpr*, *vif*, and sometimes *tev* (fusion of *tat*, *env* and *rev*) (**Table 1.1**). Although they are not compulsorily required for replication, a majority of them have distinct functions that contribute to the enhanced viral infectivity and disease progression (Bour and Strebel, 2000; Steffens and Hope, 2001; Anderson and Hope, 2003; Seelamgari *et.al.*, 2004). These regulatory genes can be separated into three categories – positive regulatory genes, negative regulatory genes and unspecified regulatory genes in which the exact functions are still largely unknown. The positive regulatory genes enhance and express regulatory proteins that promote formation of viral particles and viral infectivity while the negative regulatory genes control the level of viral infectivity (Epstein and Greene, 1991).

**Table 1.1. Summary of functions of genes encoded in HIV-1 genome.** *gag*, *env* and *pol* are precursors that produce essential proteins for HIV-1 replication. Other accessory genes indirectly regulate HIV-1 infectivity and AIDS progression.

<b>Viral gene</b>	<b>Regulation</b>	<b>Activities towards HIV/AIDS pathogenesis</b>
<i>env</i>	Structural	Encodes the outer protein coat <i>gp160</i> which then processed by a protease into <i>gp120</i> and <i>gp41</i> .
<i>gag</i>	Structural	Encodes internal proteins such as <i>p17</i> , <i>p24</i> , <i>p7</i> , and <i>p9</i> .
<i>pol</i>	Structural	Encodes the HIV core including <i>p7</i> , <i>p9</i> , RNA genome, reverse transcriptase, ribonuclease, integrase, and protease.
<i>tat</i>	Positive	A trans-activator of transcription which accelerates viral protein production of proviral genome several 1000-folds. Also up-regulates <i>rev</i> , <i>nef</i> , and itself.
<i>nef</i>	Positive	Affects cellular genes by down-modulating CD4/CD8 and MHC-I/II expression. Also negatively regulates <i>tat</i> and <i>rev</i> .
<i>rev</i>	Positive/ Negative	Increased level of <i>rev</i> enhances RNA expression and greater amount expression of Env proteins. Also down-regulates <i>tat</i> and itself and activates transport of viral mRNA from nucleus into cytoplasm.
<i>vpr</i>	Positive	A weak transcriptional activator that moderates stimulation of LTR, thus enhancing induction of HIV.
<i>vpu</i>	Negative	When <i>vpu</i> is defective, HIV replicates more quickly. Also suppresses CD4/Env interactions in the cell.
<i>vif</i>	Positive	Increases the infectivity of HIV and cell-to-cell (human-to-human) transmission. However, <i>vif</i> -deficient HIV still infects <i>in vitro</i> , but with lower kinetics.
<i>tev</i>	Positive/ Negative	A fusion protein resulting from a frameshift reading the mRNA--mixes up <i>tat/ env/ rev</i> --and apparently has full functional capacity of <i>tat</i> and <i>rev</i> .

---

MHC – major histocompatibility; LTR – long tandem repeat.

Adapted and modified from Haseltine, 1988; Epstein and Greene, 1991.

### 1.1.3. Disease control of AIDS

In the past ten years, various anti-HIV therapies targeting multiple components of the virus have been developed and some are currently under clinical trials (Maartens *et.al.*, 2014). However, the ability of HIV to develop resistance towards currently available antiviral agents has rendered the drug development challenging. Some of antiviral drugs approved by the Food and Drug Administration (FDA) are summarized in **Table 1.2**. These therapeutic agents were designed based on the understanding of establishment of HIV-1 infection, which involves multiple steps in the replication cycle. The protein-protein interaction between the virus and the host cells are the keys to unlock new therapeutic avenues (Thompson *et.al.*, 2012; Wilen *et.al.*, 2012). The HIV-1 replication cycle and the targets for potential antiviral agents are represented in **Figure 1.5**.

**Table 1.2. List of FDA-approved anti-HIV drugs.** Different classes of anti-HIV drugs were designed to target multiple components of HIV in the replication cycle.

<b>Drug Class</b>	<b>Generic Name</b>	<b>Brand Name</b>	<b>FDA Approval Date</b>
<b>Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs)</b>			
NNRTIs bind to and alter reverse transcriptase, an enzyme HIV needs to make copies of itself	Delavirdine (DLV)	Rescriptor	April 4, 1997
	Efavirenz (EFV)	Sustiva	Sep 17, 1998
	Etravirine (ETR)	Intelence	Jan 18, 2008
	Nevirapine (NVP)	Viramune	June 21, 1996
	Rilpivirine (RPV)	Edurant	May 20, 2011
<b>Nucleoside Reverse Transcriptase Inhibitors (NRTIs)</b>			
NRTIs block reverse transcriptase, an enzyme HIV needs to make copies of itself	Abacavir (ABC)	Ziagen	Dec 17, 1998
	Didanosine (ddl)	Videx	Oct 9, 1991
		Videx EC	Oct 31, 2000
	Emtricitabine (FTC)	Emtriva	July 2, 2003
	Lamivudine (3TC)	Epivir	Nov 17, 1995
	Stavudine (d4T)	Zerit	June 24, 1994
	Tenofovir DF (TDF)	Viread	Oct 26, 2001
	Zidovudine (ZDV)	Retrovir	March 19, 1987
<b>Protease Inhibitors (PIs)</b>			
PIs block HIV protease, an enzyme HIV needs to make copies of itself	Atazanavir (ATV)	Reyataz	June 20, 2003
	Darunavir (DRV)	Prezista	June 23, 2006
	Fosamprenavir (FPV)	Lexiva	Oct 20, 2003
	Indinavir (IDV)	Crixivan	March 13, 1996
	Nelfinavir (NFV)	Viracept	March 14, 1997
	Ritonavir (RTV)	Norvir	March 1, 1996
	Saquinavir (SQV)	Invirase	Dec 6, 1995
	Tipranavir (TPV)	Aptivus	June 20, 2005
<b>Fusion Inhibitors</b>			
Fusion inhibitors block HIV from entering CD4 cells of the immune system.	Enfuvirtide (T-20)	Fuzeon	March 13, 2003
<b>CCR5 Antagonists</b>			
CCR5 entry inhibitors block CCR5, a protein on the CD4 cells that HIV needs to enter the cells	Maraviroc (MVC)	Selzentry	Aug 6, 2007
<b>Integrase Inhibitors</b>			
Integrase inhibitors block HIV integrase, an enzyme HIV needs to make copies of itself	Raltegravir (RAL)	Isentress	Oct 12, 2007




**Table 1.2. Continued.**

<b>Fixed-Dose Combination</b>				
Fixed-dose combination tablets contain two or more anti-HIV medications from one or more drug classes.	Abacavir, Lamivudine	Epzicom		Aug 2, 2004
	Abacavir, Lamivudine, Zidovudine	Trizivir		Nov 14, 2000
	Efavirenz, Emtricitabine, Tenofovir DF	Atripla		July 12, 2006
	Elvitegravir, Cobicistat, Emtricitabine, Tenofovir DF	Stribild		Aug 27, 2012
	Emtricitabine, Rilpivirine, Tenofovir DF	Complera		Aug 10, 2011
	Emtricitabine, Tenofovir DF	Trueda		Aug 2, 2004
	Lamivudine, Zidovudine	Combivir		Sep 27, 1997
	Lopinavir, Ritonavir	Kaletra		Sep 15, 2000

HIV and its treatment – FDA-approved anti-HIV medications. U.S. Department of health and human services guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Reviewed on Aug 2012.


Adapted and modified from [aidsinfo.nih.gov/guidelines](http://aidsinfo.nih.gov/guidelines).



**Figure 1.5. HIV-1 replication cycle and potential antiviral targets.** A free virus interacts with a cell that contains essential receptors (CD4 and CXCR4 or CCR5) for establishment of infection. This interaction can be blocked by attachment and fusion inhibitors. Viral RNA is uncoated, reverse-transcribed, and integrated into host genome for viral protein production. Reverse transcription can be blocked by reverse transcriptase inhibitors whereas the DNA integration can be inhibited by integrase inhibitors. RNA and viral proteins assemble at the membrane for synthesis of a new viral particle. Upon the release and maturation of virus, protease acts on the Gag and Gag-Pol precursors to form an infectious particle. This step can be effectively blocked by protease inhibitors.

Adapted and modified from De Clercq, 2007.

Most anti-HIV therapies comprise single or dual agents, which target surface protein (*gp41* and *gp120*) and viral enzymes (reverse transcriptase, integrase and protease) (Peters and Conway, 2011). The strikingly rapid resistance of HIV-1 remains a huge problem until highly active antiretroviral therapies (HAART) was introduced in 1995 (Hammer *et.al.*, 1996, 1997). HAART consists of drug cocktails (combination of three to four different classes of drugs) that act on multiple targets of HIV-1 in order to interrupt the viral life cycle at different steps. Often, the drugs used in HAART are of reverse transcriptase inhibitors, protease inhibitors, and fusion inhibitors classes. This therapy has successfully controlled the infection by reducing total viral load and significantly delaying disease progression (Walensky *et.al.*, 2006; Arts and Hazuda, 2012) while dramatically diminishing the mutation rate of HIV-1 strains (Piacenti, 2006). The clinical profile that exhibits increased survival rates after introduction of HARRT is depicted in **Figure 1.6**. However, the emergence of HAART-escaped HIV-1 mutant strains remains a major concern, and other relatively effective alternatives are still under progress such as vaccine development (Rerks-Ngarm *et.al.*, 2009; Rolland *et.al.*, 2012).



**Figure 1.6. Increased survival rates of AIDS by HAART.** The development of highly active antiretroviral therapy (HAART) has been the driving force behind a revolution in the treatment of HIV/AIDS. Since the introduction of HAART in 1996, the reported new AIDS cases and AIDS-related death cases were significantly reduced by at least 50%.

Source: [hpa.org.uk/hpr/archives/2011/news2211.htm](http://hpa.org.uk/hpr/archives/2011/news2211.htm)

#### 1.1.4. Drawbacks of current therapies

Albeit the rate of disease progression being successfully suppressed by the HAART intervention (**Figure 1.6**), the drug resistance remains unresolved. Following a long exposure of drugs, the therapy will eventually become inefficient due to the acquired resistance of so-called ‘escaped mutants’. The virus will strike back and progressively destroys the immune system. Furthermore, HAART may not be efficient to all AIDS patients due to poor compliance. The patients need to adhere strictly to a dosage schedule as HAART possesses a complicated regimen requiring patients to take a series of pills at multiple times of the day (Piacenti, 2006; Peters and Conway, 2011; Arts and Hazuda, 2012), which significantly affect their life qualities. Moreover, the cost of these multiple antiviral drugs is high (Schackman *et.al.*, 2006).

HAART is also notorious of its short- and long-term side effects (**Table 1.3**). Patients under long-term treatment may also develop several clinical presentations such as lipodystrophy, hyperglycemia, diabetes, liver toxicity, and debilitating inflammatory syndrome (Jones and Núñez, 2012). These severe side effects may force the patients to skip the medication, rendering the therapy inefficient, and more crucially, promotes drug resistance. Due to these adverse effects, many cases have reported that the patients discontinued the HAART within the first year of medication (Robison *et.al.*, 2008; Cicconi *et.al.*, 2010; Woldemedhin and Wabe, 2012). With advents of these drawbacks and failure of vaccination, there is a pressing need to develop alternative therapies for controlling HIV infection.

**Table 1.3. Side effects of HAART.** Adverse effects of various drug types used in HAART.

Drug type	Adverse events
Nucleoside Reverse Transcriptase Inhibitors (NRTIs)	Nausea, diarrhea, headache, hypersensitivity syndrome, lactic acidosis, hepatic steatosis, pancreatitis, lipodystrophy, peripheral neuropathy, dyslipidemia, and renal insufficiency.
Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)	Nausea, diarrhea, headache, dizziness, Stevens-Johnson syndrome, toxic epidermal necrolysis, hyperlipidemia, hepatitis, and elevations in liver function tests.
Protease Inhibitors (PIs)	Nausea, diarrhea, headache, dyslipidemia, hyperglycemia, insulin resistance, hyperbilirubinemia, nephrolithiasis, lipodystrophy, and elevations in liver function tests.
Fusion Inhibitors	Injection site reactions, neutropenia, and possible increased frequency of pneumonia.
Chemokine Coreceptor Antagonists	Nausea, diarrhea, headache, hepatitis, joint or muscle pain, and elevations in liver function tests.
Integrase Inhibitors	Nausea, diarrhea, headache, muscle pain, and elevations in amylase and liver function tests.
Pharmacokinetic Enhancers	Nausea, diarrhea, headache, increased serum creatinine, and proteinuria

Adapted and modified from [hivinsite.ucsf.edu/InSite?page=ar-05-01#S2X](http://hivinsite.ucsf.edu/InSite?page=ar-05-01#S2X)

## 1.2. Capsid protein in HIV-1 infectivity


### 1.2.1. Biological function of capsid protein

Assembly of viral particles and their maturation into infectious particles after viral budding are indispensable steps in HIV-1 replication cycle (**Figure 1.5**). Capsid molecule (CA) or p24 is known to play important roles in early (pre-integration) and late (post-integration) events of the replication cycle (Adamson and Freed, 2007; Briant *et.al.*, 2011; Sundquist and Kräusslich, 2012). Upon cell entry, the capsid protein releases the RNAs and viral enzymes into the cell cytoplasm. Once the reverse-transcribed DNA is integrated into the host genome, viral proteins are produced and repackaged by the capsid protein for new infections.

CA is initially synthesized as a domain within a 55kDa Gag precursor polyprotein. Gag (p55) sometimes interacts with another large viral protein, Gag-Pol (160kDa) in the viral assembly. Approximately 2000-4000 copies of intact Gag polyprotein assemble at the cell membrane and bud to produce immature virus particles (Ganser-Pornillos *et.al.*, 2008, 2012) (**Figure 1.7**). The intact Gag attaches to the inner cell membrane via the myristoylated N-terminus of matrix molecule (MA), one of the cleavage products of Gag. A proteolytic cleavage by viral protease then takes place and Gag is subsequently broken into CA, MA, nucleocapsid molecule (NC), and p6 molecules. Additionally, splicing of several spacer peptides (SP) that stabilizes CA hexamers occurs sequentially to complete the Gag proteolytic process. For instance, spacer peptide-1 (SP1) stabilizes CA and NC, whereas SP2 stabilizes NC and p6 (**Figure 1.7**). In Gag-Pol protein, the Pol domain is cleaved into viral enzymes such as reverse transcriptase, protease, and integrase proteins (Meng *et.al.*, 2012).

CA develops into a cone-shaped capsid that encases the RNA genome and several viral enzymes, which then develops into mature infectious particles. Throughout the HIV-1 replication, capsid protein plays an important role in virus assembly and maturation. Without the proper assembly of capsid, mature virions cannot be formed hence affecting HIV-1 replication and infectivity. It has been reported that mutated CA in which the capsid stability was affected, significantly attenuated the HIV-1 replication (Neira, 2009; Blair *et.al.*, 2010). In recent years, the essential role of capsid protein in HIV-1 replication cycle has drawn considerable attention of researchers to study its potential to be used as antiviral targets in HIV/AIDS therapy (Neira, 2009).






**Figure 1.7. Assembly of Gag on cell membrane and its proteolytic cleavage.** After protein synthesis, HIV-1 Gag assembles on the plasma membrane to form immature particles. The Gag precursors are cleaved by viral proteases into four structural proteins (MA – matrix molecule, CA – capsid molecule, NC – nucleocapsid molecule, and *p6* - *p6* molecule) upon maturation.

Source: Ghanam *et.al.*, 2012.

### 1.2.2. Structure of capsid protein


In 2007, the three-dimensional structure of HIV-1 capsid was revealed by cryo-electron microscopy (cryoEM) (Ganser-Pornillos *et.al.*, 2007), and the complete structure of capsid in both immature and mature forms were recently studied (Bharat *et.al.*, 2012; Zhao *et.al.*, 2013). CA forms a tube-like structure *in vitro* and assembles into spherical structure (**Figure 1.8**). This protein comprises two domains and has distinct roles in stabilizing the viral capsid architecture. They are N-terminal domain (NTD), residues 1-146 that forms hexamers and C-terminal domain (CTD), residues 147-231, which is dimeric in solution (Ganser-Pornillos *et.al.*, 2007).

Each CA hexamer is composed of an inner ring of six NTDs and an outer ring of CTD (**Figure 1.9c**). Both of these independently folded domains are separated by a flexible linker but interacting closely with each other to form a compact structure (**Figure 1.9d**). Both domains predominantly compose of  $\alpha$ -helical secondary structures. The arrowhead-like NTD contains seven  $\alpha$ -helices (numbered 1–7) and an amino-terminal  $\beta$ -hairpin, while the globule-like CTD is made up of a single-turn  $3_{10}$ -helix and four short  $\alpha$ -helices (numbered 8–11) (**Figure 1.9d** and **1.9e**).



**Figure 1.8. Characterization of HIV-1 CA hexameric lattice.** Negative stain electron micrograph that shows (A) HIV-1 CA assembled into long and hollow tubes *in vitro* and (B) HIV-1 CA assembled into small spheres. The scale bar represents 100nm.

Adapted and modified from Ganser-Pornillos *et.al.*, 2007.



**Figure 1.9. Cryo-EM reconstruction of HIV-1 CA tubular assembly.** (a) A cryo-EM image of CA tubular assembly. Scale bar, 100nm. (b) Electron density map of the CA tube with helical symmetry, yellow arrows indicate pairs of helix H9, located between adjacent hexamers. (c) Molecular dynamics flexible fitting (MDFF) model of the HIV-1 capsid assembly, superimposed with the electron density map contoured at  $4.0\sigma$ , three CA hexamers, with NTDs (**blue**) and CTDs (**orange**), are shown. (d) MDFF model of a CA monomer viewed from two angles. (e) Two CTD dimer structures along -1 (**orange**) and 11 (**yellow**) helical directions, superimposed onto the NMR solution dimer structure (**grey**, 2KOD).

Adapted and modified from Zhao *et.al.*, 2013.

Structure of HIV-1 CA domains is highly associated with HIV-1 replication and infectivity. In the infectious virions, the mature CA assembles *in vitro* into three shapes: cylinders, cones, and spheres. This variation in shapes resulted from the distribution of 12 pentameric declinations within the hexameric lattice of CA. The ‘cylindrical’ capsids are obtained when tubular capsids are formed by 6 pentamers at each end of tube. An asymmetric distribution of the pentamers at the two ends results in ‘conical’ capsids while ‘spherical’ capsids arise from an even distribution of the pentamers throughout the hexameric lattice (Li *et al.*, 2000; Ganser-Pornillos *et al.*, 2004). It has been reported that the HIV-1 infectivity was reduced in the presence of virions with irregular core morphologies and heterogenous sizes of CA (Neira, 2009).

Furthermore, numerous mutagenesis studies have shown that amino acid substitutions in capsid protein lead to a reduced HIV-1 infectivity. It has been shown that mutation of arginine 18 to leucine at a site where helix-1 from the six NTDs are at their closest approach, altered the morphology of the *in vitro* assembled particles (Ganser-Pornillos *et al.*, 2004). Alanine substitutions of tryptophan 184 and methionine 185 of helix-9 in the CTD diminish the dimerization *in vitro* and HIV-1 infectivity *in vivo* (Ganser-Pornillos *et al.*, 2007). Furthermore, a single amino-acid deletion in HIV-1 CA CTD forms a ‘domain-swapped’ dimer in which its function in HIV-1 assembly and maturation was disrupted (Ivanov *et al.*, 2007). These evidences suggest that the capsid protein is a highly viable target for anti-HIV therapy.